Skip to main content
Skip to Footer

American Journal of Psychiatry

  • Volume 176
  • Number 5
  • May 2019

Editor's Note

Editorials

Commentary

Perspectives in Global Mental Health

Images in Psychiatry

Reviews and Overviews

Publication date: 01 May 2019

Pages342–347

Over the past two decades, research in the biology and treatment of major depression has led to advances in our understanding of the biology of the disorder and to the development of novel treatments. While progress has been made, a number of key issues ...

https://doi.org/10.1176/appi.ajp.2019.19030273

Articles

Publication date: 05 April 2019

Pages348–357

Objective:Almost two-thirds of patients with major depressive disorder do not achieve remission with initial treatments. Thus, identifying and providing effective, feasible, and safe “next-step” treatments are clinical imperatives. This study explores ...

https://doi.org/10.1176/appi.ajp.2018.18091079

Publication date: 29 March 2019

Pages358–366

Objective:The authors evaluated improvement in irritability with antidepressant treatment and its prognostic utility in treatment-seeking adult outpatients with major depressive disorder.Methods:Mixed-model analyses were used to assess changes in ...

https://doi.org/10.1176/appi.ajp.2018.18030355

Publication date: 08 March 2019

Pages376–387

Objective:Interest in candidate gene and candidate gene-by-environment interaction hypotheses regarding major depressive disorder remains strong despite controversy surrounding the validity of previous findings. In response to this controversy, the ...

https://doi.org/10.1176/appi.ajp.2018.18070881

Publication date: 04 January 2019

Pages388–400

Objective:The N-methyl-d-aspartate receptor antagonist ketamine produces rapid and sustained antidepressant actions even in patients with treatment-resistant depression. Vascular endothelial growth factor (VEGF) has been implicated in the effects of ...

https://doi.org/10.1176/appi.ajp.2018.17121368

Publication date: 29 March 2019

Pages401–409

Objective:Subanesthetic ketamine doses have been shown to have rapid yet transient antidepressant effects in patients with treatment-resistant depression, which may be prolonged by repeated administration. The purpose of this study was to evaluate the ...

https://doi.org/10.1176/appi.ajp.2018.18070834

Letters to the Editor

Books Received

Correction

Past Issues

View Issues Archive
No.7
View Issue
1 Jul 2024

Vol. 181 | No. 7

No.6
View Issue
1 Jun 2024

Vol. 181 | No. 6

No.5
View Issue
1 May 2024

Vol. 181 | No. 5

No.4
View Issue
1 Apr 2024

Vol. 181 | No. 4